Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patiromer - Relypsa

Next Previous
X
Search
Drug Profile

Patiromer - Relypsa

Alternative Names: ILY-105; Patiromer acetate; Patiromer calcium; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; Veltassa; ZG 801

Latest Information Update: 27 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relypsa
  • Developer Otsuka Pharmaceutical; Relypsa; Vifor Fresenius Medical Care Renal Pharma; Zeria
  • Class Polymers
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 24 Sep 2024 Preregistration for Hyperkalaemia in Japan (PO), prior to September 2024
  • 24 Sep 2024 Registered for Hyperkalaemia in Japan (PO)
  • 06 Mar 2024 Phase-II clinical trials in Hyperkalaemia (In neonates, In infants, In children) in USA (PO) (NCT05766839) (EudraCT2023-505252-21-00) (EudraCT2022-501829-20)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top